Lyra Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.29 | -$0.22 | -$0.26 |
| Q2 2024 | 3 | -$0.37 | -$0.28 | -$0.33 |
| Q3 2024 | 1 | -$0.24 | -$0.18 | -$0.22 |
| Q4 2024 | 2 | -$0.14 | -$0.12 | -$0.13 |
| Q1 2025 | 2 | -$0.11 | -$0.10 | -$0.10 |
| Q2 2025 | 1 | -$0.12 | -$0.09 | -$0.11 |
| Q3 2025 | 1 | -$0.11 | -$0.08 | -$0.10 |
| Q4 2025 | 1 | -$0.12 | -$0.09 | -$0.11 |
| Q1 2026 | 1 | -$0.20 | -$0.15 | -$0.18 |
| Q2 2026 | 1 | -$0.25 | -$0.19 | -$0.23 |
| Q3 2026 | 1 | -$0.35 | -$0.26 | -$0.31 |
| Q4 2026 | 1 | -$0.42 | -$0.31 | -$0.38 |
Lyra Therapeutics, Inc. Earnings Date And Information
Lyra Therapeutics, Inc. last posted its earnings results on Wednesday, August 14th, 2024. The company reported $-0.29 earnings per share for the quarter, topping analysts' consensus estimates of $-0.34 by $0.05. The company had revenue of 195,000 for the quarter and had revenue of 1.56 M for the year. Lyra Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.26 diluted earnings per share) and currently has a price-to-earnings ratio of -0.12. Lyra Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based on prior year's report dates.
Lyra Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2024 | Q3 2024 | -$0.18 | $315,600 | $195,000 | ||
| 08/14/2024 | Q2 2024 | -$0.34 | -$0.74 | -0.4 | $532,000 | $598,000 |
| 04/30/2024 | Q1 2024 | -$0.26 | -$0.35 | -0.09 | $532,000 | |
| 03/22/2024 | Q4 2023 | -$0.26 | $146,000 | |||
| 11/07/2023 | Q3 2023 | -$0.33 | -$0.27 | 0.06 | $371,600 | $544,000 |
| 08/08/2023 | Q2 2023 | -$0.44 | -$0.36 | 0.08 | $136,667 | $458,000 |
| 05/12/2023 | Q1 2023 | -$0.36 | -$0.44 | -0.08 | $410,000 | |
| 03/29/2023 | Q4 2022 | -$0.42 | -$0.45 | -0.03 | $11,000 | |
| 11/08/2022 | Q3 2022 | -$0.42 | -$0.40 | 0.02 | $101,750 | $359,000 |
| 08/09/2022 | Q2 2022 | -$0.34 | -$0.42 | -0.08 | $1.43 M | $407,000 |
| 05/10/2022 | Q1 2022 | -$0.92 | -$0.54 | 0.38 | $5.37 M | |
| 03/09/2022 | Q4 2021 | -$0.82 | -$1.03 | -0.21 | $271,000 | |
| 11/09/2021 | Q3 2021 | -$0.78 | -$0.85 | -0.07 | $375,000 | $14,000 |
| 08/09/2021 | Q2 2021 | -$0.61 | -$0.85 | -0.24 | $0 | |
| 05/11/2021 | Q1 2021 | -$0.48 | -$0.60 | -0.12 | $0 | |
| 03/09/2021 | Q4 2020 | -$0.61 | -$0.57 | 0.04 | $0 | |
| 11/10/2020 | Q3 2020 | -$0.48 | -$0.49 | -0.01 | $0 | |
| 08/05/2020 | Q2 2020 | -$0.37 | -$0.55 | -0.18 | $0 | |
| 05/28/2020 | Q1 2020 | -$0.34 | $0 | |||
| 12/30/2019 | Q4 2019 | -$0.69 | $0 |
Lyra Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Lyra Therapeutics, Inc.'s earnings date?
Lyra Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based off last year's report dates.
-
Did Lyra Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Lyra Therapeutics, Inc. (:LYRA) reported $-0.29 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.34 by $0.05.
-
How can I listen to Lyra Therapeutics, Inc.'s earnings conference call?
The conference call for Lyra Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Lyra Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Lyra Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Lyra Therapeutics, Inc. generate each year?
Lyra Therapeutics, Inc. (:LYRA) has a recorded annual revenue of $1.56 M.
-
How much profit does Lyra Therapeutics, Inc. generate each year?
Lyra Therapeutics, Inc. (:LYRA) has a recorded net income of $1.56 M. Lyra Therapeutics, Inc. has generated $-1.26 earnings per share over the last four quarters.
-
What is Lyra Therapeutics, Inc.'s price-to-earnings ratio?
Lyra Therapeutics, Inc. (:LYRA) has a price-to-earnings ratio of -0.12 and price/earnings-to-growth ratio is -0.02.
